Kineret (anakinra) receives positive opinion from the CHMP for treatment of patients with COVID-19 pneumonia.
EMA has recommended approval for use of Kineret in COVID-19 to the European Commission which will issue a final decision.
COVID-19 infection can lead to death due to an overreaction of the infected person’s inflammatory response, often referred to as a 'cytokine storm'. The positive opinion is based on results from the SAVE-MORE phase III study which found that early identification of candidate patients with suPAR followed by treatment with anakinra resulted in a 64% relative reduction of patients progressing into severe disease and death, in a 55% relative decrease in mortality, which reached 80% relative decrease in mortality for patients with cytokine storm. Results were published in Nature Medicine on 3 September 2021 (previously reported).
Related news and insights
Palisade Bio, Inc. announced the first patient has been dosed in its Phase III study evaluating LB 1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery.
bluebird bio, Inc. announced the FDA has approved Zynteglo (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions.
Edwards Lifesciences Corporation announced the company's PASCAL Precision transcatheter valve repair system received CE Mark for the treatment of mitral and tricuspid regurgitation (MR and TR).